Market Overview
By 2027, the global Targeted Liposomes Drug Delivery Market will be worth $6,992.95 million, with an 8.8% compound annual growth rate. The market for liposome drug delivery is being pushed by rising chronic illness prevalence, rising need for non-invasive drug delivery options, and rising pharmaceutical RD expenditures. In 2019, the liposomal doxorubicin sector held more than 36.22 percent of the market share; in terms of technology, stealth liposome technology owned the greatest market proportion in 2019; and in terms of application, the cancer treatment segment held the highest share of the market.
Market Segmentation
By Type
Doxorubicin in Pegylated Liposomes: Liposomal doxorubicin is doxorubicin enclosed in tiny spheres known as pegylated liposomes. These spheres prolong the time doxorubicin spends in the bloodstream, allowing more medicine to reach cancer cells. This kind is often used to treat cancers like ovarian cancer, breast cancer, and multiple myeloma. The increasing incidence rate of malignancies is likely to boost the expansion of this market.
Liposomal Paclitaxel: Liposomal Paclitaxel causes apoptosis by inactivating the B-cell Leukemia 2 (Bcl-2) protein, an apoptosis inhibitor. This causes this segment to be elevated. Paclitaxel liposome formulation may improve the delivery of larger paclitaxel dosages to target tissues while reducing systemic toxicity. The high efficacy rate of this type drives up the demand for its utilization.
Liposomal Amphotericin B: It is a drug used to deal with various fungal and parasite illnesses. This category is growing due to the growing number of patients with fungal infections.
Folate targeting liposomes and others are included in others.
By Application
Fungal Infection Therapy: Fungal infections are treated using liposomal medications such as Amphoteric and AmBisome. The category is expected to develop in the future as the frequency of fungal infections rises.
Cancer Therapy (Tumor Therapy): A targeted liposome drug delivery method is used in cancer therapy. Doxil and Myocet, amongst many others, are doxorubicin-based injectable polymeric nanoparticle medication formulations for cancer therapy.
Others: Liposomes seem to be a popular carrier method for vaccines and gene therapies, among other applications.
Regional Classification
Americas: Because significant participants in the Targeted Liposomes Drugs delivery sector are increasingly pursuing strategic initiatives like mergers, partnerships, acquisitions, as well as joint ventures, the Americas is estimated to be the leading regional market.
Middle East Africa: This is the smallest market due to a lack of healthcare infrastructure and the availability of novel solutions.
Asia-Pacific: In the focused liposomes drug delivery market, the Asia-Pacific area is expected to develop fastest.
Europe: The European region has the second-largest share, owing to increased legislative support and increased market awareness established by important companies.
Industry News
Chronic disease prevalence has prompted increased research and development (R RD) in liposomal drug delivery systems during the last few decades. The procedure of giving a pharmaceutical ingredient to humans to achieve a therapeutic effect is known as drug delivery. Liposomal drug delivery has several advantages, including better therapeutic effectiveness, pharmacokinetics and pharmacodynamics, and reduced toxicity, making it excellent for patients with various chronic illnesses. According to the Centers for Disease Control and Prevention (CDC), about 6 out of 10 Americans have had at least one chronic illness, and 4 out of 10 had two or more chronic illnesses in 2019.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
